Radiopharm Targets Phase 3 Start For RAD101 In Early 2027 After FDA Meeting
RAD: $0.005 +25.00% · MC: $19M
Radiopharm Theranostics says it expects to start a Phase 3 imaging trial of RAD101 in recurrent brain metastases in early 2027, following a successful end-of-Phase 2 meeting with the FDA. The company also reported positive Phase 1 imaging data for RAD301, supporting its planned progression toward Phase 2, and advanced RAD202 to its fourth dosing cohort.

Comments